Verastem promotes Robert Forrester to president

CAMBRIDGE — Verastem Inc., which is studying stem cell treatments for recurring cancers, said Tuesday that it promoted Robert Forrester to president and chief operating officer.

Forrester has been the company’s COO since May 2011.


Verastem’s most advanced drug candidate is intended to treat mesothelioma, and the company said it plans to conduct several other clinical trials in 2013.

Verastem shares rose 32 cents, or 3.2 percent, to $10.30 in midday trading. They have traded in a 52-week range of $6.25 to $12.24.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of